Literature DB >> 22574526

Acinetobacter baumannii nosocomial pneumonia in tertiary care hospitals in Thailand.

Peerawong Werarak1, Jirachai Waiwarawut, Prasit Tharavichitkul, Chaicham Pothirat, Suthat Rungruanghiranya, Sarayut Lucien Geater, Anan Chongthaleong, Chanchai Sittipunt, Pinyo Horsin, Worakij Chalermskulrat, Tawatchai Wiwatworapan, Thanason Thummakul, Piroon Mootsikapun, Noppadol Rungsrithong, Sirinya Supawita, Chareon Chuchotthavorn, Sasima Tongsai, Visanu Thamlikitkul.   

Abstract

BACKGROUND: Nosocomial pneumonia (NP) is an important cause of morbidity and mortality in hospitalized patients. Acinetobacter baumannii is one of the common causative pathogens in NP. The prevalence of multi-drug resistance in A. baumannii has been increasing. The information on clinical features and clinical courses of A. baumannii NP in Thai patients are limited.
OBJECTIVE: To determine the clinical features, risk factors and clinical courses of A. baumannii NP in Thai patients hospitalized in tertiary care hospitals in Thailand. MATERIAL AND
METHOD: This was a prospective, hospital-based, active surveillance study on hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) in adults hospitalized in 12 tertiary care hospitals in Thailand between 2008 and 2009.
RESULTS: There were 651 NP patients. A. baumannii was the most common cause of NP in 198 patients (30.4%). Most of NP patients were males with median age of 71 years. About 80% had late onset NP with the median duration of 10 days after admission in both A. baumannii and non-A. baumannii NP. Most of NP occurred in patients hospitalized in general medical wards. Most of the features of NP in A. baumannii NP and non-A. baumannii NP were not significantly different. The initial antibiotics prescribed were concordant in about 50% of the patients in both groups. Colistin was usually prescribed to the patients who received antibiotic modifications. The initial clinical responses in A. baumannii NP were less favorable than those in non-A. baumannii NP. The mortality rate in A. baumannii NP seemed to be more than that in non-A. baumannii NP. There was a trend of more persistence of pathogen in A. baumannii NP. Most isolates of A. baumannii were resistant to antibiotics including carbapenems. The patients with extensive drug resistant A. baumannii NP had less favorable responses than NP due to other bacteria, including non-extensive drug resistant A. baumannii. VAP, NP developed in medical ICU and NP with bilateral lung involvements on chest X-ray were associated with A. baumannii as the isolated pathogen.
CONCLUSION: A. baumannii is the most common causative pathogen for NP in tertiary care hospitals in Thailand and most of A. baumannii isolates were resistant to many antibiotics including carbapenems. The hospitalized patient in tertiary care hospitals with VAP, or NP that was developed in medical ICU, or NP with bilateral lung involvements on chest x-ray was likely to be due to A. baumannii. Many NP patients received inappropriate initial antibiotic regimens leading to a high mortality.

Entities:  

Mesh:

Year:  2012        PMID: 22574526

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  9 in total

1.  Preliminary clinical study of the effect of ascorbic acid on colistin-associated nephrotoxicity.

Authors:  Rujipas Sirijatuphat; Samornrod Limmahakhun; Vorapan Sirivatanauksorn; Roger L Nation; Jian Li; Visanu Thamlikitkul
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

2.  Bacterial etiology and mortality rate in community-acquired pneumonia, healthcare-associated pneumonia and hospital-acquired pneumonia in Thai university hospital.

Authors:  Jaturon Poovieng; Boonsub Sakboonyarat; Worapong Nasomsong
Journal:  Sci Rep       Date:  2022-05-30       Impact factor: 4.996

3.  Imaging mass spectrometry for assessing temporal proteomics: analysis of calprotectin in Acinetobacter baumannii pulmonary infection.

Authors:  Jessica L Moore; Kyle W Becker; Joshua J Nicklay; Kelli L Boyd; Eric P Skaar; Richard M Caprioli
Journal:  Proteomics       Date:  2013-07-24       Impact factor: 3.984

4.  A multi-center study on the risk factors of infection caused by multi-drug resistant Acinetobacter baumannii.

Authors:  Huiping Huang; Borong Chen; Gang Liu; Jing Ran; Xianyu Lian; Xinhua Huang; Nan Wang; Zhengjie Huang
Journal:  BMC Infect Dis       Date:  2018-01-05       Impact factor: 3.090

5.  Incidence, bacteriology, and clinical outcome of ventilator-associated pneumonia at tertiary care hospital.

Authors:  Harsha V Patil; Virendra C Patil
Journal:  J Nat Sci Biol Med       Date:  2017 Jan-Jun

6.  Correlation between Carbapenem Consumption and Carbapenems Susceptibility Profiles of Acinetobacter baumannii and Pseudomonas aeruginosa in an Academic Medical Center in Thailand.

Authors:  Taniya Paiboonvong; Phatchareeporn Tedtaisong; Preecha Montakantikul; Sarun Gorsanan; Woraphot Tantisiriwat
Journal:  Antibiotics (Basel)       Date:  2022-01-23

7.  Alert Germ Infections: Chest X-ray and CT Findings in Hospitalized Patients Affected by Multidrug-Resistant Acinetobacter baumannii Pneumonia.

Authors:  Raffaella Capasso; Antonio Pinto; Nicola Serra; Umberto Atripaldi; Adele Corcione; Giorgio Bocchini; Salvatore Guarino; Roberta Lieto; Gaetano Rea; Giacomo Sica; Tullio Valente
Journal:  Tomography       Date:  2022-06-14

8.  Cannabinoids from inflorescences fractions of Trema orientalis (L.) Blume (Cannabaceae) against human pathogenic bacteria.

Authors:  Tiwtawat Napiroon; Keerati Tanruean; Pisit Poolprasert; Markus Bacher; Henrik Balslev; Manop Poopath; Wichai Santimaleeworagun
Journal:  PeerJ       Date:  2021-05-13       Impact factor: 2.984

9.  In vitro activity of colistin mono- and combination therapy against colistin-resistant Acinetobacter baumannii, mechanism of resistance, and clinical outcomes of patients infected with colistin-resistant A. baumannii at a Thai university hospital.

Authors:  Yongyut Lertsrisatit; Wichai Santimaleeworagun; Sudaluck Thunyaharn; Jantima Traipattanakul
Journal:  Infect Drug Resist       Date:  2017-11-20       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.